Encyclopedia

Cerebrolysin is not a single peptide but a standardized mixture of low-molecular-weight peptide fragments (~15-25%) and free amino acids (~75-85%) produced by controlled enzymatic hydrolysis of porcine brain protein. It is registered as a medicine in over 40 countries (including Austria, Germany, Russia, and China) for stroke, traumatic brain injury, and dementia, but is not FDA-approved and remains a research-use-only compound in the United States. Its evidence base is unusually large for a peptide product but genuinely mixed: some meta-analyses show benefit, while the largest stroke trial was neutral and a Cochrane review rated dementia evidence as very low quality.

Cerebrolysin (manufactured by EVER Neuro Pharma, Austria, under development code FPF-1070) is produced by standardized enzymatic breakdown of purified porcine brain cortex protein, yielding a defined mixture of peptide fragments below 10,000 daltons plus free amino acids. Its proposed mechanism is neurotrophic-factor mimicry: peptide fragments crossing the blood-brain barrier are reported to interact with Trk receptor signaling (TrkA/TrkB) and resemble the activity of BDNF, NGF, and GDNF, engaging downstream MAPK/ERK and PI3K/Akt pathways involved in neuronal survival, synaptic plasticity, and reduction of glutamate-mediated excitotoxicity. It has an unusually large human trial base for a peptide product -- more than 50 randomized controlled trials across stroke, traumatic brain injury, vascular dementia, and Alzheimer's disease -- but the honest picture is mixed rather than uniformly positive: the largest acute-stroke trial (CASTA, n=1,070) was neutral on its primary endpoint, with only a severe-stroke subgroup showing a trend toward benefit; a 2023 Cochrane review (PMID 37818733) concluded moderate-certainty evidence that Cerebrolysin probably has no effect on all-cause mortality or functional independence after acute ischemic stroke; and a separate Cochrane review of the vascular-dementia evidence rated it 'very low quality' with high risk of bias, noting that nearly all positive trials were funded by the manufacturer. Side-effect rates across trials have consistently been comparable to placebo. It is registered as an approved medicine in more than 40 countries but has never received FDA approval and is not available as a legal prescription product in the United States.

Mechanism of Action

Proposed to act through neurotrophic-factor mimicry: its low-molecular-weight peptide fraction crosses the blood-brain barrier and is reported to interact with Trk receptor signaling (TrkA, TrkB), activating MAPK/ERK and PI3K/Akt pathways involved in neuronal survival, synaptic plasticity, and neurogenesis, resembling the activity of endogenous BDNF, NGF, and GDNF. Also proposed to modulate glutamate-mediated excitotoxicity and support protein-clearance pathways. As an undefined, multi-component mixture rather than a single molecular entity, its pharmacology is inherently harder to characterize than a synthetic peptide.